Home Molecular Dx Liquid Biopsies

Liquid Biopsies

Latest
ersonal Genome Diagnostics (PGDx) said today that its 500+ gene pan-cancer tumor profiling tissue assay is being used by Merck & Co. in a Phase II clinical trial designed to assess patient response to a dual biomarker-directed precision oncology combination therapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC).
Liquid Biopsies

Biocept’s NSCLC Liquid Biopsy Gains Coverage from Insurer Highmark

Liquid Biopsies

Freenome Raises $270M in Series C Financing for Cancer Tests Based...

Liquid Biopsies

FDA Approves First NGS-Based Liquid Biopsy Companion Diagnostic

|Epic Science’s lab
Liquid Biopsies

It’s in the Blood

Skin cancer, light micrograph
Liquid Biopsies

Low Amounts of ctDNA Can Predict Good Immunotherapy Outcome

Liquid Biopsies

Guardant, Radius Partner to Develop CDx for Breast Cancer Drug Elacestrant

Liquid Biopsies

Thrive Raises $257M in Series B to Advance CancerSEEK Liquid Biopsy

Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. [Source: © Alex Tihonov/Fotolia]
Liquid Biopsies

Canadian Consortium Backs Liquid Biopsy Solution to Increase Cancer Testing Access...

Projections for the growth of the liquid biopsy market range as low as $1 billion by 2020
Liquid Biopsies

Study Finds Liquid Biopsy Insurance Coverage Growing but Incomplete

Liquid Biopsies

Brain Tumor Liquid Biopsy Detects DNA Methylation Profiles

Load more

New Products

View More
Load more
Copyright © 2020 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up